Maxtra DC

Maxtra DC Drops

The combination of Levodropropizine and Chlorpheniramine Maleate offers a dual-action approach for the symptomatic relief of cough and allergic components in upper respiratory tract infections.

Levodropropizine, a peripheral antitussive, acts at the level of airway sensory nerves to suppress cough without affecting the central nervous system ensuring safety and alertness.

CPM, a first-generation antihistamine, complements this by controlling allergy-related symptoms like sneezing, runny nose, and nasal congestion.

Together, they interrupt the cough-allergy cycle, providing effective and well-tolerated relief in chronic cough associated with RTI, Asthma, Bronchitis. This is also ideal for dry irritating cough associated with allergy, post nasal drip without the drowsiness or dependence associated with central cough suppressants.

Maxtra C

Maxtra C Drop Logo

Cetirizine drops offer effective and gentle relief from allergic symptoms in infants and young children. As a second-generation antihistamine, cetirizine provides fast onset of action—typically within an hour and ensures 24-hour, relief from conditions like allergic rhinitis, urticaria, and environmental allergies.

With a child-friendly taste and precise weight-based dosing, cetirizine drops are easy to administer and well tolerated, making them a trusted choice for Doctors.

Designed specifically for tiny tummies, they combine safety, efficacy, and comfort in every drop.

Efficacy and Safety of Once-Weekly Trelagliptin As Compared to Twice-Daily Vildagliptin in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Phase 3, Non-inferiority Clinical Trial

Cureus Journal Cover Page Zuventus
Download PDF
Download PDF

Abstract

Background

Trelagliptin and vildagliptin are oral dipeptidyl peptidase-4 (DPP-4) inhibitors used in the treatment of type 2 diabetes mellitus. The administration of vildagliptin is twice daily, whereas trelagliptin provides the convenience of once-weekly dosing, which may enhance patient adherence. A phase 3 clinical trial was conducted to assess the non-inferiority of trelagliptin compared to vildagliptin.

Methods

This multicenter, randomized, open-label, parallel-group, active-controlled non-inferiority clinical trial was conducted at 10 geographically distinct sites across India. A total of 240 treatment-naive patients with type 2 diabetes mellitus were randomized in a 1:1 ratio to receive either trelagliptin (100 mg once weekly) or vildagliptin (50 mg twice daily) for 16 weeks. The primary endpoint was non-inferiority of trelagliptin to vildagliptin in reducing glycated hemoglobin (HbA1c) levels from baseline to week 16. Secondary efficacy measures included changes in fasting and postprandial blood glucose, fasting insulin, glucagon, C-peptide, and glucagon-like peptide-1 (GLP-1) levels. Safety was assessed based on the incidence of adverse events.

Results

At week 16, the mean HbA1c levels were 7.18 ± 1.47% and 7.21 ± 1.49% in trelagliptin and vildagliptin groups, respectively (Δ -0.89% vs. Δ -1.00%, p < 0.0001). The difference between groups was 0.11% (95% CI: -0.28 to 0.50; p = 0.5899), showing non-inferiority of trelagliptin. A total of 48.57% of patients in the trelagliptin group and 47.57% in the vildagliptin group achieved the target HbA1c level of <7% (p = 0.8850). No statistically significant differences were observed between the groups for glycemic parameters, including fasting blood glucose (Δ 1.11; 95% CI: -16.79 to 19.02; p = 0.9025), 2-hr postprandial glucose (Δ 3.33; 95% CI: -30.55 to 23.88; p = 0.8093), fasting serum insulin (Δ 5.22; 95% CI: -15.01 to 25.45; p = 0.6113), fasting glucagon (Δ 0.72; 95% CI: -96.34 to 94.90; p = 0.9882), C-peptide (Δ 0.36; 95% CI: -0.31 to 1.03; p = 0.2912), and GLP-1 levels (Δ -0.02; 95% CI: -0.06 to 0.02; p = 0.3995). All reported adverse events were mild in nature and resolved without any lasting effects. Adverse events occurred in 6.67% (8/120) of patients in the trelagliptin group and 9.17% (11/120) in the vildagliptin group.

Conclusions

Trelagliptin showed a significant reduction in HbA1c, fasting, and postprandial glucose levels, indicating effective glycemic control in patients with type 2 diabetes mellitus. The study drug exhibited a favorable safety profile, with no major adverse events reported. Overall, trelagliptin proved to be both efficacious and well-tolerated, demonstrating non-inferiority to vildagliptin.

Citation

Dewan B, Shinde S, Roy S. Efficacy and Safety of Once-Weekly Trelagliptin As Compared to Twice-Daily Vildagliptin in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Phase 3, Non-inferiority Clinical Trial. Cureus. 2025;17(6):e85219. DOI 10.7759/cureus.85219.

Plecasoft

Plecasoft Tablets
Plecasoft contains the active ingredient plecanatide, which works directly in the intestine to help increase fluid and support regular bowel movements. It acts like a natural substance in your body to draw water into the intestines, making stools softer and easier to pass. This makes stools softer and easier to pass. It helps relieve symptoms like hard stools, bloating, and stomach discomfort. Plecasoft is used in adults to treat long-term(chronic) constipation and constipation caused by irritable bowel syndrome (IBS-C).

Upnuron-D

Upnuron-D for neuropathic pain

The combination of ‘Pregabalin and Duloxetine’ is an emerging, fast-growing therapy for Painful Peripheral Neuropathy associated with Mood Disorders. Upnuron-D, offers enhanced efficacy in relieving neuropathic pain while helping regulate mood. Upnuron-D, provides patients with effective pain relief and mood stabilization, promoting overall well-being.

Reperi Gel

Reperi Gel for neurotic pain

Topical Pregabalin 8% is an emerging therapy for Diabetic Neuropathic Pain. This targeted formulation is designed to reduce pain while minimizing adverse effects. Reperi Gel, provides patients with an effective solution that manages discomfort and minimizes systemic side effects, helping them lead a more comfortable life.

Bevon NH

Bevon NH Softgel Capsules

Bevon-NH is a comprehensive blend of essential multi-vitamins, minerals, and antioxidants formulated to ensure well-being of Nerve Health. Bevon-NH, helps alleviate symptoms of Nutritional Deficiency & Diabetic/ Peripheral Neuropathy. By addressing Nerve-related discomfort, Bevon-NH not only relieves pain but also promotes holistic wellness.